Author:
Koc Ö.M.,Verbeek J,Koek G.H.,Bielen R,Busschots D,Gamil M,Robaeys G,Nevens F
Abstract
Background and study aims: There is ongoing debate whether antiviral therapy should be initiated in hepatitis B e antigen (HBeAg)-negative patients with normal alanine aminotransferase (ALT) levels but high HBV DNA levels >2,000 IU/mL. Since the need for antiviral therapy might be different between Asian and Caucasian patients, we studied the long-term disease outcome in Caucasian patients living in Western Europe.
Patients and methods: One hundred sixteen patients with high HBV DNA levels (>2,000 IU/mL) at diagnosis were included in the high viremia group, while those with HBV DNA <2,000 IU/mL were used as controls (n = 327). All patients were Caucasian, HBeAg negative, had normal ALT levels and had no significant liver disease at diagnosis.
Results: Median follow-up was 7 + 9.8 years in the high viremia group and this was 10 + 12.5 years in controls. The cumulative probability of a liver-related event over 10 years was 4.8% vs 0.0% in the control group (p=.008). In multivariable analysis, high viremia group was associated with the occurrence of a liver-related event (hazards ratio (HR) 95% confidence interval (CI): 1.20-11.98, p=.023). In this subgroup, older age at diagnosis (HR 95% CI: 1.01-1.16, p=.023) predicted a higher risk of liver-related event. In the high viremia group, liver-related mortality was 0.9% and none of the patients developed hepatocellular carcinoma.
Conclusions: HBV DNA >2,000 IU/mL influences the long-term disease outcome in Caucasian HBeAg-negative patients living in Western Europe. Nevertheless, the risk of liver-related events is low.
Reference46 articles.
1. WORLD HEALTH ORGANIZATION, 2018, Hepatitis B, World Health Organization, viewed 5 May 2018 .
2. SARIN S.K., KUMAR M., LAU G.K., ABBAS Z., CHAN H.L., CHEN C.J., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int., 2016, 10(1): 1-98.
3. TERRAULT N.A., LOK A.S.F., MCMAHON B.J., CHANG K.M., HWANG J.P, JONAS M.M., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018; 67(4): 1560-99.
4. EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology, 2017, 67(2): 370-98.
5. CHEN C.J., YANG H.I., SU J., JEN C.L., YOU S.L., LU S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295(1): 65-73.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献